The identification of different stages within the alcohol use disorder (AUD) cycle that are linked to neurocircuitry changes in pathophysiology associated with the negative emotional states of abstinence has provided a view of medication development for AUD that emphasizes changes in the brain reward and stress systems. Alcohol use disorder can be defined as a chronic relapsing disorder that involves compulsive alcohol seeking and taking, loss of control over alcohol intake, and emergence of a negative emotional state during abstinence. The focus of early medications development was to block the motivation to seek alcohol in the binge/intoxication stage. More recent work has focused on reversing the motivational dysregulations associated with the withdrawal/negative affect and preoccupation/anticipation stages during protracted abstinence. Advances in our understanding of the neurocircuitry and neuropharmacological mechanisms that are involved in the development and maintenance of the withdrawal/negative affect stage using validated animal models have provided viable targets for future medications. Another major advance has been proof-of-concept testing of potential therapeutics and clinical validation of relevant pharmacological targets using human laboratory models of protracted abstinence. This review focuses on future targets for medication development associated with reversal of the loss of reward function and gain in brain stress function that drive negative reinforcement in the withdrawal/negative affect stage of addiction. Basic research has identified novel neurobiological targets associated with the withdrawal/negative affect stage and preoccupation/anticipation stage, with a focus on neuroadaptive changes within the extended amygdala that account for the transition to dependence and vulnerability to relapse.
Conceptual framework for medications development in alcohol use disorder
Alcohol Use Disorder (AUD) is a chronic, relapsing disorder that has been characterized by a compulsion to seek and take alcohol, the loss of control over alcohol intake, and the emergence of a negative emotional state (e.g., dysphoria, anxiety, and irritability) that defines a motivational withdrawal syndrome when access to alcohol is prevented. Moderate to severe AUD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (American Psychiatric Association, 2013) , can be considered to be operationally equivalent to the syndrome of alcoholism. Alcohol use disorder, like addiction, has been conceptualized as a threestage cycledbinge/intoxication, withdrawal/negative affect, and preoccupation/anticipationdthat involves disruption in incentive salience, reward and stress, and executive function, respectively, mediated by changes in the corresponding neurocircuitry (for review, see Koob and Volkow, 2016) . These neuroadaptations represent a break with homeostasis in the motivational domain and have been argued to represent a readjustment of parameters at a new set point but outside the homeostatic range, known as allostasis. In this context, both the loss of reward system function and the sensitization of stress systems lead to malaise, hypohedonia, anxiety, dysphoria, negative affect, pain, irritability, and sleep disturbances (defined as motivational withdrawal symptoms) which can drive alcohol seeking via negative reinforcement. Negative reinforcement is defined as the process by which removal of an aversive stimulus (or aversive state of abstinence from compulsive alcohol taking in the case of AUD) increases the probability of a response (relapse to drinking). Given the hypothesis that such negative reinforcement is one of the major driving factors for compulsivity in AUD, the reversal of reward deficits and stress surfeit in the withdrawal/negative affect stage of the AUD cycle becomes a compelling source of targets for medications for AUD.
Clinical trials: challenges and opportunities
Double-blind, placebo-controlled trials with random assignment to treatments are the accepted standard for determining drug efficacy in AUD. A primary challenge is obtaining access to an investigational compound with an approved Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) so that the drug can be tested in humans (see Koob et al., 2009 , for further information regarding INDs for medications for the treatment of addiction), or identifying a drug already approved for another indication that could be repurposed for AUD.
There are then a number of unique features of clinical trials for medications for the treatment of AUD. These include challenges regarding the definition of clinically relevant outcome measures, admission criteria, and methods for detecting relapse to alcohol use between study visits. Issues related to adherence (formerly called "compliance"), placebo response, and drop-out rates continue to present challenges to the design and conduct of clinical trials in AUD. There are also AUD-specific safety and tolerability issues, particularly the potential pharmacokinetic and pharmacodynamic interactions between alcohol and the drug under study (for further details, see Koob et al., 2009 ).
3. Human laboratory studies: screening drugs that target the withdrawal/negative affect stage in alcohol use disorder Human laboratory studies are a potentially powerful means of exploring treatment targets for specific components of the AUD cycle, independent of expensive and lengthy double-blind, placebocontrolled trials. Using the AUD cycle framework (Fig. 1) , human laboratory studies provide validated measures for each of the stages of AUD and have heuristic value for predicting potential treatment efficacy in these domains (Koob et al., 2009) . In particular, accumulating data demonstrate the predictive validity of human laboratory models for medications that focus on the withdrawal/ negative affect stage. Such models may include personalized stressful scripts and exposure to in vivo alcohol cues in abstinent alcoholics. The success of drugs for AUD in the real world will ultimately provide the proof-of-principle of the validity of animal models combined with human laboratory models as a springboard for the development of novel medications for AUD (Koob et al., 2009; Koob and Mason, 2016) .
A model of stress-induced responsivity involves the playback of personalized stressful auditory scripts developed with the subject and recorded at the previous visit (Sinha, 2009 ). This method is based on the early work of Lang (1980) and elicits stress-related responses and stress-induced craving in individuals with AUD in a human laboratory setting. Here, individuals who used higher amounts of alcohol per week and subjects who were recovering from alcohol dependence showed greater craving and physiological responses to stressors compared with controls (i.e., social drinkers; Fox et al., 2007) . From a validation perspective, stress-induced alcohol craving in the laboratory significantly predicted time to relapse (al'Absi et al., 2005) and showed positive results for prazosin (Fox et al., 2012) . Studies that cross-reference pharmacological probes from animal and human studies can provide further support for the construct validity and predictive validity of pharmacological targets for AUD and may provide an excellent basis for advancing compounds into the clinic.
A novel approach to screen potential therapeutics for reducing the risk of drinking relapse in protracted abstinence is the use of the cue reactivity model to evaluate the efficacy of medications (relative to placebo) in suppressing alcohol-induced craving in abstinent alcoholics ). Non-treatment-seeking paid volunteers with current AUD are exposed to affective stimuli with positive or negative content and then to a beverage cue (their preferred alcohol beverage or bottled water control) but with no opportunity to self-administer alcohol. Exposing abstinent alcoholics to alcohol cues following the induction of affective states that are commonly linked to drinking relapse may serve as a powerful stressor in brain systems that are intrinsic to drinking relapse. Cue reactivity can be measured using subjective craving and psychophysiological measures (Mason et al., 2008) , including heart rate, skin conductance, and facial electromyograms. Alcohol exposure and both positive and negative emotional cues are associated with significantly increased subjective craving, with confirmatory but less specific effects on psychophysiological measures (Mason et al., 2008) . Gabapentin significantly decreased subjective alcoholevoked craving in this model and also improved several measures of sleep quality in abstinent alcoholics . These outcomes were confirmed in independent clinical trials of gabapentin in AUD (Furieri and Nakamura-Palacios, 2007; Brower et al., 2008; Mason et al., 2014) . The convergence of human laboratory and clinical trial results suggest that cue reactivity, combined with an emotional overlay, may provide a powerful means of evaluating potential medications for the withdrawal/negative affect stage of protracted abstinence in AUD. Particularly compelling about this approach is that it reliably predicts efficacy in human double-blind, placebo-controlled trials. Positive results have been observed for three medications that showed efficacy in human laboratory studies and in double-blind, placebo-controlled trials: acamprosate, gabapentin, and pregabalin (Jonas et al., 2014; Mason et al., 2009 Mason et al., , 2014 Mason, 2015a; Mason, 2015b) . Additionally, the suppression of alcohol-induced craving in this model by administration of the glucocorticoid antagonist mifepristone, relative to placebo, predicted subsequent decreased drinking posttreatment . Particularly compelling is that these same medications also yielded positive results in animal models of withdrawal-induced drinking (see Koob and Mason, 2016) .
4. Neurobiological mechanisms in alcohol use disorder that are relevant to novel targets for the development of medications associated with protracted abstinence
As noted above and previously reviewed, two processes are hypothesized to form the neurobiological basis for the withdrawal/ negative affect stage: loss of function in the reward systems and recruitment of the brain stress systems in the extended amygdala (Koob and Mason, 2016; Tunstall et al., 2017) . The extended amygdala has been conceptualized to be composed of several basal forebrain structures, including the bed nucleus of the stria terminalis (BNST), central nucleus of the amygdala (CeA), sublenticular substantia innominata, and a transition zone in the medial part of the nucleus accumbens (NAc; e.g., shell; Heimer and Alheid, 1991) . As motivational withdrawal symptoms, defined above, develop, the brain reward systems become compromised. There are decreases in dopamine cell firing and dopamine D 2 receptors, both hypothesized to reflect hypodopaminergic states (Volkow et al., 2007) , with additional changes in opioid transduction mechanisms that contribute to alcohol withdrawal (Chen and Lawrence, 2000) . Brain stress systems, such as corticotropin-releasing factor (CRF), norepinephrine, dynorphin, hypocretin, and substance P, are also recruited, producing aversive or stress-like states, and brain antistress systems, such as neuropeptide Y (NPY), are downregulated (Koob and Le Moal, 2008; Carlezon et al., 2000) . The thesis here is that the loss of reward systems and the recruitment of the central stress systems develop during the withdrawal/negative affect stage and persist into protracted abstinence (in the preoccupation/anticipation stage). Thus, the combination of decreases in reward neurotransmitter function and recruitment of brain stress systems provides a powerful motivation for relapse during both acute and protracted abstinence.
The global function of the prefrontal cortex is to engage executive function, and deficits in executive function are one of the hallmarks of AUD, particularly in the preoccupation/anticipation stage. However, superimposed on these deficits in executive function in the preoccupation/anticipation stage are residual deficits that carry over from the withdrawal/negative affect stage, termed protracted abstinence. Individuals with substance use disorders exhibit disruptions of executive function, such as impaired decision making and behavioral inhibition, which can contribute to craving, but the residual subcortical dysregulations associated with the binge/intoxication and withdrawal/negative affect stages probably are the driving force of relapse (Koob and Mason, 2016; Marlatt and Gordon, 1980) .
A plethora of druggable targets can be derived from the basic neurobiology of AUD but remain a challenge for drug development because of the lack of INDs, lack of human laboratory testing, and the extraordinary expense of properly powered clinical trials. Briefly, the targets for each stage of the AUD cycle will be addressed but with a focus on neurobiological targets that are based on efficacy in models of the motivational components of the withdrawal/ negative affect stage of the AUD cycle. Much early work focused on direct antagonism of the reinforcing effects of alcohol, representing the binge/intoxication stage, but such drugs can produce side effects that limit compliance (Mitchell et al., 2009 ). Thus, the following section will focus on two major domainsdrestoring reward system tone and decreasing brain stress system tonedas targets for medications development in AUD.
Reward modulators: partial agonists
Two neurochemical systems in the basal forebrain have been implicated in alcohol reward: the mesocorticolimbic dopamine system and the opioid peptide system (Koob, 2014) . The mesocorticolimbic dopamine system projects from the ventral tegmental area to basal ganglia forebrain sites, such as the NAc and CeA, and has been hypothesized to play a key role in incentive salience by directing behavior toward salient rewarding stimuli (Schultz, 2007) . As such, activation of the mesocorticolimbic dopamine system appears to be involved in the incentive salience actions of alcohol. Opioid peptides in the basal ganglia and their transduction of activity via m opioid receptors also play a key role in alcohol reward. They mediate affiliative behavior and hedonic responses and play a key role in the reinforcing effects of opioids and alcohol (Le Merrer et al., 2009; Mitchell et al., 2012) . The a4b2 subunit of nicotinic acetylcholine receptors (nAChRs) has long been hypothesized to mediate rewarding effects via the phasic activation of signaling by dopamine and is intimately involved in the expression of nicotine reward and reinforcement and possibly alcohol reward (Tolu et al., 2013) .
More importantly for the reward deficit contribution to the negative emotional state that drives compulsive alcohol seeking, both dopaminergic and opioidergic function are significantly compromised during acute withdrawal from alcohol (Weiss et al., 1992; Diana et al., 1993 Diana et al., , 1995 Nestler, 1996) . Animals that are sustained on an alcohol liquid diet during withdrawal show a decrease in extracellular levels of dopamine in the NAc (Weiss et al., 1996) . Withdrawal from most major drugs of abuse is associated with decreases in the firing of dopaminergic neurons in the ventral tegmental area (Melis et al., 2005) . Withdrawal from alcohol is accompanied by dramatic alterations in signal transduction mechanisms also associated with withdrawal from opioid peptides and opiates (Ron and Barak, 2016) . Perhaps even more compelling, imaging studies have documented hypofunction in dopamine pathways during protracted withdrawal, reflected by a decrease in dopamine D 2 receptor expression and a decrease in dopamine release for alcohol (Koob and Volkow, 2016) .
Partial agonists can be defined as drugs that bind to a receptor and have low efficacy, often with high affinity. As such, partial agonists will show antagonism when there is high agonist tone but agonism when there is low agonist tone. In terms of the AUD cycle outlined above, partial agonists could theoretically block the reinforcing effects of alcohol during the binge/intoxication stage but in addition block or blunt the negative motivational effects that characterize the withdrawal/negative affect stage. Two medications that are on the market for the treatment of addiction, buprenorphine and varenicline, have exactly such effects.
Buprenorphine is an oripavine derivative that is an opioid receptor partial agonist. It is an effective maintenance therapy for opioid addiction (Mello and Mendelson, 1980) and is widely used as a first-line treatment for addiction to opioids such as heroin and oxycodone, and to treat pain (Koob and Mason, 2016) . Buprenorphine is functionally considered a partial agonist at m and d opioid receptors and at nociception/orphanin (NOP) receptors, and an antagonist at k receptors. Differences in effects of buprenorphine depend on what opioid action is being measured. Buprenorphine has partial or full agonist properties in animal tests of analgesia, depending on the test employed. In humans, it is a full agonist for analgesia. Buprenorphine has a ceiling effect for producing respiratory depression, consistent with a partial agonist-like effect for this measure. However, use of buprenorphine with CNS depressants (e.g., alcohol or benzodiazepines) is contraindicated, as such combinations may lead to fatal respiratory depression (Center for Substance Abuse Treatment, 2004) . Buprenorphine has been shown to have a dual action on alcohol consumption per se . At low doses, it increased ethanol drinking in alcohol-preferring rats, an effect found with m agonists and that was blocked by pretreatment with naltrexone. Conversely, at high doses, buprenorphine decreased ethanol intake, and this effect was not modified by naltrexone but was blocked by pretreatment with a selective NOP receptor antagonist, suggesting the NOP against properties of buprenorphine may offer a target for medication development .
Varenicline is a partial a4b2 nAChR agonist that decreases relapse rates in smoking cessation in humans (Jorenby et al., 2006) . Varenicline decreases nicotine-induced dopamine release in the NAc in vivo but also reverses the decrease in dopamine release of nicotine withdrawal (Rollema et al., 2007; Foulds et al., 2013) and decreases motivational measures of nicotine withdrawal (Igari et al., 2014; Foulds, 2006) . Varenicline also has shown positive effects for the treatment of AUD in an multicenter, double-blind, placebo-controlled clinical trial, in which varenicline lowered weekly percent heavy drinking days, drinks per drinking day, and alcohol craving compared with the placebo group (Litten et al., 2013) .
Given the role of dopamine in the acute reinforcing effects of drugs and its dysregulation during drug withdrawal, a reasonable hypothesis is that a more direct approach to re-regulating the reward deficit associated with the withdrawal/negative affect stage of the AUD cycle would be to develop a dopamine partial agonist. Indeed, dopamine D 2 partial agonists dose-dependently decreased the reinforcing effects of oral alcohol self-administration in nondependent rats (Pulvirenti and Koob, 2002) . However, placebocontrolled studies with the partial agonist aripiprazole in the treatment of AUD have shown inconsistent results Voronin et al., 2008) , and dopamine-modulating drugs typically are associated with significant side effects. To date, no clinical studies have been performed with D 1 and D 3 partial agonists in AUD.
Glutamate modulators
Glutamate has been hypothesized to play key roles in the neurobiology of craving in AUD, particularly alcohol-primed and cue-induced craving, and could provide potential targets for medications development. One hypothesis that may be compatible with subcortical changes involves glutamate dysregulation of the frontal cortex and the preoccupation/anticipation stage. Repeated selfadministration of psychostimulants decreases the basal release of glutamate in key brain circuits that are associated with frontal cortex function, but an exaggerated glutamate response of activity in these circuits could convey sensitivity to relapse (Kalivas et al., 2003) . For example, cue-induced reinstatement involves a glutamatergic projection to the NAc from both the basolateral amygdala and ventral subiculum (Everitt and Wolf, 2002; Vorel et al., 2001 ).
a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, N-methyl-D-aspartate (NMDA) receptor antagonists, metabotropic glutamate-2/3 receptor agonists, and metabotropic glutamate-5 receptor antagonists, all of which decrease glutamate function, have been shown to block cueinduced reinstatement (Backstrom and Hyytia, 2006) .
Acute and protracted abstinence from alcohol that is described in preclinical models of AUD appears to involve overactive glutamatergic systems and is a target for the actions of acamprosate (de Witte et al., 2005; Littleton, 2007; Spanagel and Kiefer, 2008) . Acamprosate, approved by the FDA for the treatment of AUD, is clinically effective in maintaining abstinence in alcohol dependence (Jonas et al., 2014; Maisel et al., 2013) and is a functional antagonist of NMDA receptors, possibly via an action at regulatory polyamine sites, and it may also act directly on metabotropic glutamate receptors to decrease glutamate activity (Littleton, 2007) . Studies with the anticonvulsant compound topiramate provide evidence of a potential AMPA/kainate target for glutamate modulation in AUD. Topiramate blocks AMPA/kainate receptors, in addition to allosterically modulating ion channel conductance (Shank et al., 2000) . Double-blind, placebo-controlled clinical trials have reported decreases in drinking behavior in AUD and improvements in quality of life but with significant adverse effects on memory and concentration (Stringer et al., 2008; Olmsted and Kockler, 2008) . Preclinical studies showed that topiramate decreased stress-induced increases in alcohol consumption and preference in mice (Farook et al., 2009 ). These results suggest that targeting the AMPA/kainate receptor system may be a strategy for restoring stress homeostasis. To date, however, side effects of topiramate itself appear to limit acceptability for routine clinical use in AUD.
CRF, glucocorticoid, and dynorphin-k opioid receptor antagonists: brain stress systems as targets for medications for alcohol use disorder
As noted above, brain neurochemical systems within the neurocircuitry of the brain stress systems mediate stress modulation and are activated during acute withdrawal from alcohol (Koob, 2008) . Both the hypothalamic-pituitary-adrenal (HPA) axis and extrahypothalamic brain stress system that are mediated by CRF are dysregulated by chronic and/or compulsive administration of alcohol, with a common response of elevated adrenocorticotropic hormone (ACTH), glucocorticoids, and amygdala CRF during acute withdrawal (Koob, 2013) . Activation of the HPA response may also be an early dysregulation associated with excessive drinking that ultimately "sensitizes" the extrahypothalamic CRF systems (Koob and Kreek, 2007; Vendruscolo et al., 2012) .
In rodent models, CRF receptor antagonists reverse anxiety-like and aversive-like responses during acute withdrawal and protracted abstinence from chronic and compulsive use of alcohol (Koob, 2013) . CRF antagonists blocked the increased selfadministration of alcohol in dependent rats during both acute withdrawal and protracted abstinence (Funk et al., 2007; Rimondini et al., 2002; Valdez et al., 2002; Gehlert et al., 2007) . When administered directly into the CeA, a CRF 1 /CRF 2 antagonist blocked alcohol self-administration in alcohol-dependent rats (Funk et al., 2006) . CRF antagonists also reversed the elevation in reward thresholds produced by alcohol withdrawal (Bruijnzeel et al., 2010) . All of these effects have been hypothesized to be mediated by actions in the extended amygdala (Koob, 2013) . Human laboratory studies involving stress-induced craving methods (see above) evaluated the CRF 1 antagonists pexacerfont and verucerfont in treatment-seeking anxious alcoholics after 3 weeks of treatment in an inpatient unit (Kwako et al., 2015; Schwandt et al., 2016) . Neither study found a drug effect on craving outcomes. The authors speculated that the effects of CRF 1 antagonists in preclinical models of AUD may not translate to humans with AUD. Alternatively, human laboratory studies typically test non-treatmentseeking outpatient alcoholics after a few days of abstinence, whereas the milieu effects of a 3-week inpatient stay in the treatment-seeking participants in these two studies may have blunted factors that underlie drug response.
Chronic alcohol use disrupts and dysregulates the HPA axis, and clinical reports have shown impaired stress responsivity in alcoholics (Lovallo et al., 2000; O'Malley et al., 2002; Adinoff et al., 2005) . Although some individuals with AUD actually present symptomatology that mimics Cushing's syndrome (characterized by high glucocorticoids in blood), excessive HPA axis activation more commonly results in a blunted HPA axis response (for review, see Edwards et al., 2015) . Drugs that are used to prevent relapse to heavy drinking, such as opioid receptor antagonists, activate the HPA axis, and sensitivity to this activation is most predominant in subjects with a strong family history of AUD (O'Malley et al., 2002; Wand et al., 1999; Kiefer et al., 2006) . Animal models have shown similar effects, with a blunted corticosterone response in rats that were made dependent using the chronic intermittent alcohol vapor model (Richardson et al., 2008) . Oral alcohol self-administration in rats stimulates the HPA axis to release ACTH and corticosterone but at the same time drives neuroadaptive changes in extrahypothalamic CRF systems in the extended amygdala. High corticosterone increases CRF mRNA in the CeA and lateral BNST, and decreases CRF mRNA in the paraventricular nucleus of the hypothalamus (Albeck et al., 1997; Makino et al., 1994a Makino et al., , 1994b Shepard et al., 2000; Schulkin et al., 1998) , thus contributing to both the blunted HPA response to chronic high-dose alcohol exposure and sensitization of the extrahypothalamic CRF responses. Thus, initial exposure to high corticosterone, stimulated by moderate to heavy drinking, may stimulate CRF expression in the CeA and lateral BNST, eventually leading to neuroadaptive changes, including further sensitization of CRF activation in the extended amygdala and decreased HPA function (Richardson et al., 2008) . Glucocorticoid receptor signaling in the HPA axis and extrahypothalamic system may be a potential target for drug development because of a putative dual role, i.e., normalize reward function and desensitize stress systems.
Another neuropeptide that has long been hypothesized to contribute to negative emotional states is dynorphin. Hyperactivation of dopamine and opioid peptides has been hypothesized to produce subsequent activation of dynorphin systems, which in turn was hypothesized to decrease (via negative feedback) dopamine release and contribute to the dysphoric syndrome associated with drug withdrawal (Carlezon et al., 2000; . Dynorphins produce aversive dysphoric-like effects in animals and humans and have been hypothesized to mediate negative emotional states in general and more specifically to be associated with drug withdrawal (Koob, 2013; Shippenberg et al., 2007; Wee and Koob, 2010) . The dynorphin-k opioid system also mediates compulsive-like alcohol seeking associated with dependence in rodents. Excessive, compulsive-like alcohol self-administration can also be blocked by k opioid receptor antagonists (Walker et al., 2010) , and one site of action is hypothesized to be the shell of the NAc (Nealey et al., 2011) .
Other pro-stress, pro-dysphoria-inducing brain neurotransmitter systems converge on the extended amygdala. In addition to CRF and dynorphin, evidence shows that norepinephrine, vasopressin, substance P, and hypocretin (orexin) may all contribute to negative emotional states associated with drug withdrawal, particularly alcohol withdrawal (Koob, 2008 (Koob, , 2013 Edwards et al., 2012; Barbier et al., 2013; Edwards et al., 2015; Schmeichel et al., 2015) . Indeed, a recent multi-site, randomized controlled clinical trial showed that participants who received ABT-436, a novel vasopressin 1b antagonist that blocks a key receptor of the stress neurotransmitter, vasopressin, experienced more days of alcohol abstinence. Furthermore, participants who reported high levels of stress responded better to ABT-436 as evidenced by decreases in both the frequency of drinking and the number of heavy drinking days (Ryan et al., 2017) . Again, a likely target for these actions is the extended amygdala, suggesting that multiple distributed systems from the brainstem and hypothalamus converge in the extended amygdala to contribute to negative emotional states.
Neuropeptide Y, nociceptin, endocannabinoids and oxytocin: emotional buffer systems as targets for medications for alcohol use disorder
Activation of the pro-stress systems promotes the negative emotional states that drive negative reinforcement during acute withdrawal and protracted abstinence and is multi-determined. However, a multi-determined anti-stress buffering system that may help return the organism to homeostasis when activated has also been hypothesized (Koob, 2008) . Preclinical studies have identified four prominent neurotransmitter/neuromodulator systems that play a role in buffering the actions of pro-stress neurotransmitter systems: NPY, nociceptin, and endocannabinoids and oxytocin.
Neuropeptide Y is a neuropeptide that is hypothesized to exert effects that are opposite to CRF in the negative motivational state of withdrawal from drugs of abuse (Heilig and Koob, 2007) . Neuropeptide Y has significant anxiolytic-like properties and is localized to multiple brain regions but also innervates the amygdala, a site hypothesized to be involved in its anxiolytic-like effects in rodents (Koob, 2013; Heilig and Koob, 2007) . The hypothesis is that NPY acts as a buffer or homeostatic response to between-system neuroadaptations that can homeostatically regulate emotional systems in the brain (Heilig and Koob, 2007; Valdez and Koob, 2004) .
Two other neurotransmitter systems, nociceptin and endocannabinoids, may have effects that buffer activation of the brain stress systems. Nociceptin (also known as orphanin FQ), is the endogenous ligand for the NOP receptor (formerly referred to as opioid receptor-like-1; Meunier et al., 1995; Reinscheid et al., 1995) . Nociceptin generally attenuates stress-like responses and has a broad anxiolytic-like profile that extends to animal models of AUD (Ciccocioppo et al., 2003; Martin-Fardon et al., 2010) . Substantial evidence shows increases in endocannabinoid production in response to stress and as such can regulate negative emotional states (Patel et al., 2005) . The elevation of brain extracellular levels of endocannabinoids through the inhibition of endocannabinoid metabolism or reuptake mechanisms produces anxiolytic-like effects in various animal models of anxiety, particularly under stressful or aversive conditions, and a reduction of cannabinoid CB 1 receptor signaling can produce anxiogeniclike behavioral effects (Parsons and Hurd, 2015) . Evidence also shows that drug-seeking behavior can be blocked by inhibiting endocannabinoid clearance (Parsons and Hurd, 2015; Serrano and Parsons, 2011) . As with the other stress buffers discussed above, one could hypothesize that endocannabinoids play a protective role in preventing drug dependence by buffering stress activation associated with withdrawal, and thus, dysregulations in endocannabinoid function may also contribute to the negative affective disturbances associated with drug dependence and protracted withdrawal.
Oxytocin is a neuropeptide that is an emerging candidate as a stress buffer, which may have a role in modulating susceptibility to the development of dependence. Preclinical studies have shown that oxytocin inhibits the development of tolerance to multiple abused drugs, including alcohol, and may impact the development of dependence through its interactions with multiple systems, including dopamine, HPA axis and immune systems (Kov acs et al., 1998) .
Oxytocin is currently under investigation for the treatment of alcohol use disorder and withdrawal. Preliminary work has shown that intranasal oxytocin was superior to placebo in reducing symptoms of relatively mild alcohol withdrawal (Pedersen et al., 2013) , and had a dual effect on alcohol craving in a human lab study: more socially anxious subjects with alcohol abuse showed decreased craving, and less socially anxious subjects showed increased craving, with oxytocin relative to placebo (Mitchell et al., 2016) . A survey of clinicaltrials.gov indicates a number of studies are currently investigating the therapeutic potential of oxytocin in alcohol use disorder.
Molecular-cellular correlates predict medication targets
Molecular-cellular changes load the neurocircuits that drive the motivational set points described above that contribute to compulsive alcohol seeking. Such molecular targets become potential medication targets and range from molecules involved in the transduction of receptor-mediated events to growth factors that are involved in the regulation of growth, maintenance, proliferation, and survival of target neurons to transcription factors that activate specific genes. For example, it has long been known that chronic alcohol alters the function of cyclic adenosine monophosphate (cAMP)-dependent protein kinases, and the inhibition of protein kinases decreases alcohol consumption (Ron and Barak, 2016) .
Targeting ubiquitous growth factors, such as brain-derived neurotrophic factor, in specific neurocircuits provides a means of more specifically accessing molecular targets of stress systems in specific brain regions to reverse the negative emotional states that drive compulsive alcohol seeking (Moonat et al., 2011) . There are dynamic, short-term, and long-lasting changes that occur in the transcription factors DFosB, cAMP response element binding protein (CREB), and nuclear factor kB after chronic alcohol administration that modulate the synthesis of proteins that are involved in key aspects of synaptic plasticity associated with the AUD phenotype (Nestler, 2012) . Such molecular targets also mediate cellular actions in the neurocircuitry discussed above; the actions of alcohol in the extended amygdala provide a representative example. Alcohol enhances the release of g-aminobutyric acid (GABA) from GABAergic afferents or interneurons via either release from the same terminal, such as CRF, which then acts on CRF 1 receptors on the terminal to elicit the release of more GABA via a protein kinase Cε-mediated mechanism, or direct activation of CRF 1 receptors to elicit the release of more GABA (Bajo et al., 2008) . CRF 1 antagonists and the drug gabapentin decrease presynaptic GABA release in dependent animals (Roberto et al., , 2010 , and both CRF 1 antagonists and gabapentin block dependence-induced drinking in animal models. Gabapentin has also been shown to have efficacy in clinical trials (Brower et al., 2008; Furieri and Nakamura-Palacios, 2007; Mason et al., 2014; Tunstall et al., 2017) . k-Opioid antagonists may have similar effects as CRF 1 antagonists on cellular activity in the CeA . Thus, CRF, dynorphin, and alcohol have been hypothesized to augment the inhibition of CeA projection interneurons (co-containing CRF, opioids, or NPY), leading to the excitation of downstream neurons through disinhibition (see Roberto review, this issue). Thus, the cellular actions parallel the neuropharmacological effects in animal models of compulsive drug taking and seeking, leading to a powerful preclinical framework for future drug development . A focus on restoring motivational homeostasis by reversing acute withdrawal and protracted abstinence associated with the withdrawal/negative affect and preoccupation/anticipation (craving) stages of the addiction cycle reveals numerous preclinical targets for medications development for addiction.
Future molecular-genetic approaches to predict medication targets
The advent of "big data" in science has highlighted other approaches that capitalize on new information regarding moleculargenetic components involved in the neurocircuitry of brain development/plasticity and consequently have promise for identifying targets for interventions in addiction, some of which may not require a drug. From a molecular perspective, the National (Nussinov and Tsai, 2015; Day et al., 2015) . Another National Institutes of Health initiative aims at "Illuminating the Druggable Genome" (https://commonfund.nih.gov/idg/index; accessed January 20, 2017) to improve our understanding of the properties and functions of proteins that are currently unannotated within the four most commonly drug-targeted protein families: Gprotein-coupled receptors, nuclear receptors, ion channels, and protein kinases. Collectively, these innovative programs provide the scientific community with the resources and knowledge to propel and enable major discoveries in drug development to improve health and combat complex diseases.
Multiple genetic markers have been identified through classic genome-wide association studies (see Reilly review, this issue), and attempts are now being made to identify specific single-nucleotide polymorphisms (SNPs) in the human population that may predict not only vulnerability to endophenotypes associated with specific stages of the addiction cycle but also ultimately responses to medications. Work on genetic association studies that have focused on the dysregulated stress systems outlined above are limited, but there are some preliminary studies with CRF and NPY.
A number of polymorphisms in human CRF system molecules have been associated with excessive alcohol use phenotypes, particularly in interactions with stress history. An association was found between binge drinking in adolescents and alcoholdependent adults and SNPs of the CRF 1 receptor gene (Treutlein et al., 2006) , and one of the SNPs could potentially influence transcription of the CRF 1 receptor gene. Furthermore, a stress history was shown to produce greater increases in future alcohol intake (Blomeyer et al., 2008; Schmid et al., 2010) and an earlier onset of drinking (Schmid et al., 2010) in adolescents who were homozygous for a SNP of the Crhr1 gene. Crhr1 SNPs also predicted greater alcohol consumption in individuals who were already dependent (Treutlein et al., 2006) , and significant associations were found between P3 amplitude and alcohol dependence and multiple SNPs in the Crhr1 gene (Chen et al., 2010) .
Associations were also found between SNPs in the NPY2R gene and alcohol dependence, alcohol withdrawal symptoms, and comorbid alcohol and cocaine dependence (Wetherill et al., 2008) . The specific polymorphism of the NPY gene has been linked to alcohol dependence (Bhaskar et al., 2013) . Thus, should a medication become available that blocks CRF or facilitates NPY neurotransmission, one could speculate that some specific human genetic subgroups might be more responsive. Indeed, observations in a clinical study of AUD treatment with acamprosate that baseline serum glutamate levels are significantly higher in responders compared with non-responders and that serum glutamate levels of responders are normalized after acamprosate treatment, whereas there was no significant glutamate change in non-responders, suggest that there is a genetic predisposition that can predict responsiveness to acamprosate, suggesting ultimately a means of predicting which patients are likely to respond to which medication (Nam et al., 2015) .
Summary and conclusions
The thesis of this review is that medications development for AUD can benefit from use of a heuristic framework for stages of the AUD cycle linked to neurocircuitry and that dysregulation in the brain reward and stress systems that result in the symptoms of acute and protracted abstinence during the withdrawal/negative affect and preoccupation/anticipation stages of the AUD cycle are a neglected focus for drug development for AUD. Much previous work on medications for AUD focused on blocking the rewarding effects of drugs in the binge/intoxication stage of the AUD cycle, but identification of a clear role for the motivational signs of withdrawal as reflected by negative emotional states in the withdrawal/ negative affect stage represent a compelling rationale for focusing on neurobiological targets in this domain. The dramatic surge in our understanding of the neurocircuitry and neuropharmacological mechanisms that are involved in the development and maintenance of the withdrawal/negative affect stage have provided numerous unique and viable targets for future drug development. Human laboratory models of the withdrawal/negative affect stage permit proof-of-concept testing of potential therapeutics, as well as preclinical and clinical validation of relevant pharmacological targets. Such a domain approach rather than syndrome approach to drug development has the potential to reveal novel targets for drug development for AUD.
